• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign

    3/31/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email

    The Brand's Latest Mineral Sunscreen Addresses

    Top Consumer Barriers to Daily Sunscreen Use

    SUMMIT, N.J., March 31, 2025 /PRNewswire/ -- Kenvue Inc. (NYSE:KVUE) continues to push the boundaries of suncare product development with the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70. A December 2024 Kenvue research study found that 99% of healthcare providers believe if sunscreen offered better application and aesthetic experiences, patients would use their sunscreen more often1. The new mineral formula addresses these barriers by offering a high SPF with a lightweight, invisible finish. To raise awareness, the #1 suncare brand2 in the U.S. is launching a new campaign with an unexpected partner, actor and WWE Superstar John Cena, who, like the new sunscreen, is known for being invisible.

    Inspired by the legendary 'You Can't See Me' catchphrase, the Sunscreen You Can't See campaign reinforces that while you may not see Ultra Sheer ® Sunscreen on your skin, the high-SPF mineral formula is working hard to protect you from the harshest UV rays. Joining Cena in the campaign is dermatologist and skin cancer surgeon Dr. Neera Nathan.

    "I had a blast working on this campaign. It's funny, but it also gets across a really important point—wearing SPF every day isn't something you should skip," said John Cena. "Neutrogena® Ultra Sheer ® Sunscreen is lightweight, not greasy, and honestly, it's so sheer you barely notice it's there."

    "As a dermatologist who removes skin cancers daily, I know sun protection is crucial for preventing sun-induced cancers and photoaging," says Dr. Neera Nathan. "Ultra Sheer ® Mineral Face Liquid Sunscreen stands out for its lightweight, high-SPF mineral protection and invisible finish, which I hope will encourage more people to wear sunscreen daily."

    The Neutrogena® Ultra Sheer ® Sunscreen collection is designed for everyday wear, offering superior broad-spectrum UVA/UVB protection powered by proprietary Helioplex® and Purescreen® Technology. The advanced, fast-absorbing mineral formula ensures an ultra-light, invisible finish without the heavy, greasy feel, making sunscreen use effortless and enjoyable.

    "At Neutrogena®, we're committed to breaking down barriers to sun protection," said Andrew Stanleick, Kenvue President of Skin Health & Beauty in North America, Europe, Middle East, and Africa. "By leveraging humor and cultural relevance, we're making sun safety and daily sunscreen use a conversation people want to engage with, especially younger audiences."

    In 2025, Neutrogena® is strengthening its longstanding commitment to education and awareness for sun safe practices, while increasing the number of dermatologists engaged and sunscreen sampled. As the official sun care sponsor of the Coachella Valley Music and Arts Festival and Stagecoach Festival, the brand will offer complimentary sunscreen stations and education. Additionally, Neutrogena® is deepening its eight-year relationship with the Melanoma Research Foundation, surpassing $1 million in total donations over their relationship and partnering to host activations during Melanoma Awareness Month.

    Furthering its impact, the brand will serve as an official sun care sponsor of the 2025 World Surf League, emphasizing the importance of sun protection for beach and water activities. To reach younger audiences, Neutrogena® has partnered with Young Minds Inspired to develop the Sun Safety for All program, providing education to students across the country and fostering lifelong sun protection habits at an early age.

    About Kenvue

    Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

    About Neutrogena®

    For over 90 years, Neutrogena® has been developing breakthrough skincare solutions that both advance clinical efficacy and provide incredible product experience, living into our Beauty to a Science platform. From science-led innovation to accessible education, we are driven by a mission to democratize skin health & beauty. Our products address skin needs across ages, skin types and tones. Neutrogena® is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc.

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.

    A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

    1 Sunscreen Perception Survey 2024 (December 2024) Kenvue – Dermsquared®

    2 Nielsen L52W ending 12/28

    Media Contact: 

    Jenni Évora 

    Communications Lead, Neutrogena

    [email protected]

    Actor and WWE Superstar, John Cena, and Neutrogena® are redefining the concept of invisible sunscreen.

    Actor and WWE Superstar, John Cena, is the global face of the latest Neutrogena® Ultra Sheer SPF campaign.

    Neutrogena Reveals New Brand Positioning Blending Beauty and Science Without Compromise (PRNewsfoto/Kenvue Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neutrogena-and-john-cena-team-up-for-the-ultimate-disappearing-act-in-new-ultra-sheer--mineral-sunscreen-campaign-302415025.html

    SOURCE Kenvue Inc.

    Get the next $KVUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    1/30/2026$18.00Buy → Hold
    Jefferies
    10/29/2025$15.00Buy → Hold
    Canaccord Genuity
    9/26/2025$22.00Neutral → Buy
    Rothschild & Co Redburn
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    More analyst ratings

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operations Officer Stevens Meredith converted options into 5,170 shares and covered exercise/tax liability with 2,096 shares, increasing direct ownership by 3% to 93,621 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/12/26 7:14:51 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Chief People Officer Alvarado Luani converted options into 4,222 shares and covered exercise/tax liability with 2,078 shares, increasing direct ownership by 4% to 61,415 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/12/26 7:14:44 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Group President EMEA & LA Lawson Carlton converted options into 6,158 shares, increasing direct ownership by 6% to 111,415 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/12/26 7:14:38 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

    3/27/26 10:17:43 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 10-K filed by Kenvue Inc.

    10-K - Kenvue Inc. (0001944048) (Filer)

    2/20/26 7:13:06 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    2/17/26 4:46:12 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

    Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ:KMB) and Kenvue Inc. (NYSE:KVUE) today announced that Kimberly-Clark and Kenvue shareholders voted overwhelmingly to approve all of the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue at their respective Special Meetings of Stockholders held today. "We are grateful to Kimberly-Clark shareholders who voted resoundingly in support of our combina

    1/29/26 9:27:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kenvue downgraded by Jefferies with a new price target

    Jefferies downgraded Kenvue from Buy to Hold and set a new price target of $18.00

    1/30/26 6:43:10 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

    10/29/25 7:19:36 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

    9/26/25 8:00:14 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Jeffrey C bought $110,986,526 worth of shares (6,377,694 units at $17.40) (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/15/25 4:00:25 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary